Electrodiagnostic Subtyping in Guillain-Barré Syndrome Patients in the International Guillain-Barré Outcome Study

Background And Purpose: Various electrodiagnostic criteria have been developed in Guillain-Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria.

Methods: From the first 1500 patients in IGOS, nerve conduction studies from 1137 (75.8%) were available for the current study. These patients were classified according to nerve conduction studies criteria proposed by Hadden and Rajabally.

Results: Of the 1137 studies, 68.3% (N = 777) were classified identically according to criteria by Hadden and Rajabally: 111 (9.8%) axonal, 366 (32.2%) demyelinating, 195 (17.2%) equivocal, 35 (3.1%) inexcitable and 70 (6.2%) normal. Thus, 360 studies (31.7%) were classified differently. The areas of differences were as follows: 155 studies (13.6%) classified as demyelinating by Hadden and axonal by Rajabally; 122 studies (10.7%) classified as demyelinating by Hadden and equivocal by Rajabally; and 75 studies (6.6%) classified as equivocal by Hadden and axonal by Rajabally. Due to more strictly defined cutoffs fewer patients fulfilled demyelinating criteria by Rajabally than by Hadden, making more patients eligible for axonal or equivocal classification by Rajabally. In 234 (68.6%) axonal studies by Rajabally the revised El Escorial (amyotrophic lateral sclerosis) criteria were fulfilled; in axonal cases by Hadden this was 1.8%.

Conclusions And Discussion: This study shows that electrodiagnosis in GBS is dependent on the criterion set utilized, both of which are based on expert opinion. Reappraisal of electrodiagnostic subtyping in GBS is warranted.

Citing Articles

Clinical and electrophysiological features of pure sensory Guillain-Barré syndrome: retrospective analysis of 22 patients across 14 provinces in Southern China.

Liu S, Chu H, Peng B, Zeng Y, Liu J, Lu Z BMC Neurol. 2025; 25(1):87.

PMID: 40050755 PMC: 11883962. DOI: 10.1186/s12883-025-04103-w.

Guillain-Barré syndrome.

Leonhard S, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs B Nat Rev Dis Primers. 2024; 10(1):97.

PMID: 39702645 DOI: 10.1038/s41572-024-00580-4.

Electrodiagnostic subtyping in Guillain-Barré syndrome patients in the International Guillain-Barré Outcome Study.

Arends S, Drenthen J, de Koning L, Van den Bergh P, Hadden R, Kuwabara S Eur J Neurol. 2024; 31(9):e16335.

PMID: 38965709 PMC: 11295174. DOI: 10.1111/ene.16335.

References

Arends S, Drenthen J, de Koning L, Van den Bergh P, Hadden R, Kuwabara S . Electrodiagnostic subtyping in Guillain-Barré syndrome patients in the International Guillain-Barré Outcome Study. Eur J Neurol. 2024; 31(9):e16335. PMC: 11295174. DOI: 10.1111/ene.16335. View

Rajabally Y, Durand M, Mitchell J, Orlikowski D, Nicolas G . Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?. J Neurol Neurosurg Psychiatry. 2014; 86(1):115-9. DOI: 10.1136/jnnp-2014-307815. View

van Asseldonk J, van den Berg L, Kalmijn S, Wokke J, Franssen H . Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37 degrees C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy. Brain. 2005; 128(Pt 4):880-91. DOI: 10.1093/brain/awh375. View

Arends S, Drenthen J, Van den Bergh P, Franssen H, Hadden R, Islam B . Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clin Neurophysiol. 2022; 138:231-240. DOI: 10.1016/j.clinph.2021.12.014. View

Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S . Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis. Clin Neurophysiol. 2017; 128(7):1176-1183. DOI: 10.1016/j.clinph.2017.03.048. View

Feinberg D, Preston D, Shefner J, Logigian E . Amplitude-dependent slowing of conduction in amyotrophic lateral sclerosis and polyneuropathy. Muscle Nerve. 1999; 22(7):937-40. DOI: 10.1002/(sici)1097-4598(199907)22:7<937::aid-mus19>3.0.co;2-6. View

Uncini A, Kuwabara S . Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015; 86(11):1186-95. DOI: 10.1136/jnnp-2014-310097. View

Iijima M, Arasaki K, Iwamoto H, Nakanishi T . Maximal and minimal motor nerve conduction velocities in patients with motor neuron diseases: correlation with age of onset and duration of illness. Muscle Nerve. 1991; 14(11):1110-5. DOI: 10.1002/mus.880141112. View

Cornblath D, Kuncl R, Mellits E, Quaskey S, Clawson L, Pestronk A . Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 1992; 15(10):1111-5. DOI: 10.1002/mus.880151009. View

10.

Meulstee J, van der Meche F . Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry. 1995; 59(5):482-6. PMC: 1073708. DOI: 10.1136/jnnp.59.5.482. View

11.

Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M . IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol. 1998; 44(2):202-8. DOI: 10.1002/ana.410440210. View

12.

Shefner J, Al-Chalabi A, Baker M, Cui L, de Carvalho M, Eisen A . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020; 131(8):1975-1978. DOI: 10.1016/j.clinph.2020.04.005. View

13.

Leonhard S, van der Eijk A, Andersen H, Antonini G, Arends S, Attarian S . An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort. Neurology. 2022; 99(12):e1299-e1313. DOI: 10.1212/WNL.0000000000200885. View

14.

Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R . Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2010; 29(3):599-612. DOI: 10.1016/j.vaccine.2010.06.003. View

15.

Jacobs B, van den Berg B, Verboon C, Chavada G, Cornblath D, Gorson K . International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst. 2017; 22(2):68-76. DOI: 10.1111/jns.12209. View

16.

Daube J . Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve. 2000; 23(10):1488-502. DOI: 10.1002/1097-4598(200010)23:10<1488::aid-mus4>3.0.co;2-e. View

17.

Brooks B, Miller R, Swash M, Munsat T . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):293-9. DOI: 10.1080/146608200300079536. View

18.

Ho T, Mishu B, Li C, Gao C, Cornblath D, Griffin J . Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118 ( Pt 3):597-605. DOI: 10.1093/brain/118.3.597. View

19.

. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978; 3(6):565-6. DOI: 10.1002/ana.410030628. View

20.

Souayah N, Pahwa A, Jaffry M, Patel T, Nasar A, Chong Z . Electrodiagnostic profile of conduction slowing in amyotrophic lateral sclerosis. Heliyon. 2023; 9(8):e18400. PMC: 10382630. DOI: 10.1016/j.heliyon.2023.e18400. View